Alka Chaubey Net Worth

Alka Chaubey biography

Dr. Alka Chaubey Ph.D. has been appointed as Chief Medical Officer of the Company effective 8/31/2020. Dr. Chaubey comes to Bionano with almost 20 years of scientific and clinical experience, including at PerkinElmer, where she currently serves as the Head of Cytogenomics for PerkinElmer Genomics and for Vanadis. She holds an academic appointment as the Scientific Director of the Georgia Esoteric and Molecular Laboratory, Scientific Director of the Cytogenetics Laboratory of the Augusta University Medical Center and Adjunct Assistant Professor of Pathology of the Medical College of Georgia at Augusta University. Previously, Dr. Chaubey was Director of the Cytogenomics Laboratory of the Greenwood Genetic Center. Her breadth of clinical experience spans an array of clinical indications, including constitutional disorders, non-invasive prenatal Testing (NIPT) assay for common aneuploidies, the FDA Laboratory Developed Test (LDT-EUA) submissions for COVID-19 assays, a Bionano Saphyr-based test for Facioscapulohumeral Muscular Dystrophy (FSHD1) and other sequencing based tests, including whole genome sequencing. She was also central in the FDA clearance for the first IVD whole genome microarray, CytoScan DX from Affymetrix, now part of Thermo Fisher Scientific. Dr. Chaubey is widely respected as a thought leader and innovator in the cytogenetic and molecular diagnostic community, serving on multiple advisory boards and consortia management boards.

What's Alka Chaubey's mailing address?

Alka's mailing address filed with the SEC is C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO, CA, 92121.

Insiders trading at Bionano Genomics Inc

Over the last 6 years, insiders at Bionano Genomics Inc have traded over $0 worth of Bionano Genomics Inc stock and bought 145,814 units worth $129,149 . The most active insiders traders include David L Barker, Christopher P. Stewart oraz Christopher J Twomey. On average, Bionano Genomics Inc executives and independent directors trade stock every 75 days with the average trade being worth of $15,253. The most recent stock trade was executed by Hannah Mamuszka on 13 June 2023, trading 65,789 units of BNGO stock currently worth $50,000.

What does Bionano Genomics Inc do?

at bionano genomics®, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. our team is not afraid to venture into uncharted territory to look for answers. we welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home. our next-generation genome mapping and analysis tools help researchers see true genome structure to fill in what’s missing from sequencing-based data. saphyr™, our high-speed, high-throughput whole genome mapping solution, offers unmatched structural variation discovery capabilities and the ability to construct the most complete genome assemblies. at bionano, we are invested in the success of our customers and users around the world, and are dedicated to supporting them with the tools, resources and support they need to achieve their goals and make a real impact on improving quality o

Bionano Genomics Inc executives and stock owners

Bionano Genomics Inc executives and other stock owners filed with the SEC include:

• R. Erik Holmlin,
  President, Chief Executive Officer, Director
• Mark Oldakowski,
  Chief Operating Officer
• Dr. Robert Erik Holmlin,
  Pres, CEO, Sec. & Director
• David Barker,
  Independent Chairman of the Board
• Christopher P. Stewart,
  Chief Financial Officer
• Kristiina Vuori,
  Independent Director
• Christopher Twomey,
  Independent Director
• Albert Luderer,
  Independent Director
• Hannah Mamuszka,
  Director
• Yvonne Linney,
  Director
• Alka Chaubey,
  Chief Medical Officer
• Christopher Stewart,
  Chief Financial Officer
• Dr. Charles Lee Ph.D.,
  Scientific Advisor
• Prof. Pui-Yan Kwok,
  Scientific Advisor
• Dr. Paul R. Selvin Ph.D.,
  Scientific Advisor
• Mark Adamchak,
  Controller
• Richard Shippy,
  Chief Bus. Officer
• Robert J. Priar,
  Chief Commercial Officer
• Dr. Alka Chaubey FACMG, Ph.D.,
  Chief Medical Officer
• Aleksandar Rajkovic,
  Director
• Robert J Priar,
  Chief Commercial Officer
• Michael James Ward,
  Former Chief Financial Officer
• Heather Adams,
  Chief Administrative Officer
• Warren Robinson,
  Chief Commercial Officer
• Darren Cai,
  Director
• Quan Zhou,
  Director
• Junfeng Wang,
  Director
• Soheil Shams,
  Chief Informatics Officer
• Richard Shippy,
  Chief Business Officer
• Vincent Jung Fai Wong,
  Director
• Jonathan V. Dixon,
  GENERAL COUNSEL
• Gulsen Kama,
  Chief Financial Officer